Elanco Animal Health (NYSE:ELAN) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Elanco Animal Health (NYSE:ELAN) posted its quarterly earnings results on Wednesday. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.26 by $0.08, Briefing.com reports. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The company’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.45 earnings per share.

Elanco Animal Health Stock Up 1.9 %

ELAN stock traded up $0.31 during mid-day trading on Thursday, hitting $17.21. 7,407,675 shares of the company were exchanged, compared to its average volume of 4,585,274. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.35 and a current ratio of 2.75. Elanco Animal Health has a 1-year low of $7.88 and a 1-year high of $17.43. The firm has a market cap of $8.50 billion, a P/E ratio of -6.79, a P/E/G ratio of 1.42 and a beta of 1.34. The firm’s 50 day simple moving average is $14.98 and its 200 day simple moving average is $14.04.

Insider Activity

In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were bought at an average cost of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the acquisition, the director now directly owns 185,000 shares of the company’s stock, valued at $2,985,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of research reports. Barclays boosted their price target on shares of Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research report on Thursday. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Finally, The Goldman Sachs Group upped their target price on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.29.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.